消癌平注射液联合沙利度胺辅助放化疗对中晚期食管癌患者肿瘤标志物、血管内皮生长因子及其受体表达的影响(1)
摘要 目的：探討消癌平注射液联合沙利度胺辅助放化疗对中晚期食管癌患者肿瘤标志物、血管内皮生长因子(VEGF)及其受体表达的影响。方法：选取2012年1月至2016年6月南阳医学高等专科学校第一附属医院收治的中晚期食管癌患者160例为研究对象，入院序号为奇数序号者为对照组，偶数序号者为观察组，每组80例。2组均给予常规化疗，对照组在常规化疗的基础上给予三维适形放疗，观察组在对照组的基础上应用消癌平注射液联合沙利度胺治疗，21 d为1个治疗周期，连续治疗3个周期，并随访2年。观察2组近期及远期疗效;比较2组治疗前后血清中肿瘤标志物、VEGF及其受体表达;统计2组治疗及随访不良反应发生情况。结果：治疗后观察组RR为75.00%，明显高于对照组的56.25%( P <0.05)，观察组1年生存率为96.25%，显著高于对照组的86.25%( P <0.05)。治疗后2组吞咽困难、泛吐痰涎、腹痛腹泻及四肢困乏等主要中医证候积分均较治疗前显著下降，且观察组显著低于对照组，差异有统计学意义( P <0.05)。治疗后2组血清中巨噬细胞炎性蛋白-3α(MIP-3α)、糖类抗原125(CA125)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)及细胞角质蛋白19片段(CYFRA21-1)、VEGF及内皮生长因子受体-1(VEGFR-1)表达均较治疗前显著下降，差异有统计学意义( P <0.05)，且观察组明显低于对照组，差异有统计学意义( P <0.05)。治疗及随访中观察组呕吐、白细胞下降、放射性食管炎及骨髓抑制的发生率显著低于对照组，差异有统计学意义( P <0.05)。结论：消癌平注射液联合沙利度胺辅助放化疗可显著降低中晚期食管癌患者血清肿瘤标志物水平，抑制VEGF及其受体表达，改善患者临床症状的同时降低不良反应发生率，提升临床疗效。
关键词 中晚期食管癌;放疗;消癌平注射液;沙利度胺;肿瘤标志物;血管内皮生长因子
Effects of Xiaoaiping Injection Combined with Thalidomide Adjuvant Radiotherapy and Chemotherapy on the Expression of Tumor Markers，VEGF and its Receptors in Patients with Middle and Late Esophageal Cancer
Nan Haifeng1，Ding Lei2
(1 Gastroenterology Department，First Affiliated Hospital of Nanyang Medical College，Nanyang 473058，China; 2 Ophthalmology of the Second People′s Hospital of Puyang City，Puyang 426000，China)
Abstract Objective： To study the effects of Xiaoaiping Injection combined with thalidomide adjuvant radiotherapy and chemotherapy on the expression of tumor markers，vascular endothelial growth factor (VEGF) and its receptors in patients with middle and late esophageal cancer. Methods： A total of 160 cases of patients with middle and late esophageal cancer treated in the First Affiliated Hospital of Nanyang Medical College from January 2012 to June 2016 were selected as the study objects，the number of odd numbers was the control group，and the even number was the observation group，with 80 cases in each group. The 2 groups were given conventional chemotherapy，and the control group was given three dimensional conformal radiotherapy on the basis of conventional chemotherapy. The observation group was treated with Xiaoaiping Injection combined with thalidomide on the basis of the control group，21 days for a treatment cycle，both had 3 consecutive cycles and follow-up for 2 years. The short-term and long-term effects of the 2 groups were observed，and the levels of the serum tumor markers，VEGF and its receptors in the 2 groups were compared before and after treatment，the occurrence of toxic side effects in treatment and follow-up in the 2 groups were statisticsed. Results： The RR of the observation group was 75.00%，which was significantly higher than that 56.25% of the control group after treatment ( P <0.05); 1 year survival rate of the observation group was 96.25%，which was significantly higher than 86.25% of the control group ( P <0.05). The scores of main TCM symptoms such as dysphagia，pan-sputum and salivation，abdominal pain，diarrhea and quadriplegia in the 2 groups after treatment were significantly lower than those before treatment，and the scores in the observation group were significantly lower than those in the control group ( P <0.05 or P <0.01). The expression levels of MIP-3α，CA125，CEA，NSE，CYFRA21-1，VEGF，VEGFR-1 in serum of the 2 groups were significantly lower than those before treatment ( P <0.01)，the observation group was obviously lower than the control group ( P <0.01). The incidence of vomiting，leukopenia，radiation esophagitis and bone marrow depression in the observation group were significantly lower than those in the control group during treatment and follow-up ( P <0.05 or P <0.01). Conclusion： Xiaoaiping Injection combined with thalidomide adjuvant radiotherapy and chemotherapy can significantly reduce the levels of serum tumor markers in patients with middle and late esophageal cancer，inhibit the expression of VEGF and its receptor，improve the clinical symptoms and reduce the incidence of toxic side effects and improve the clinical efficacy., http://www.100md.com(南海峰 丁磊)
关键词 中晚期食管癌;放疗;消癌平注射液;沙利度胺;肿瘤标志物;血管内皮生长因子
Effects of Xiaoaiping Injection Combined with Thalidomide Adjuvant Radiotherapy and Chemotherapy on the Expression of Tumor Markers，VEGF and its Receptors in Patients with Middle and Late Esophageal Cancer
Nan Haifeng1，Ding Lei2
(1 Gastroenterology Department，First Affiliated Hospital of Nanyang Medical College，Nanyang 473058，China; 2 Ophthalmology of the Second People′s Hospital of Puyang City，Puyang 426000，China)
Abstract Objective： To study the effects of Xiaoaiping Injection combined with thalidomide adjuvant radiotherapy and chemotherapy on the expression of tumor markers，vascular endothelial growth factor (VEGF) and its receptors in patients with middle and late esophageal cancer. Methods： A total of 160 cases of patients with middle and late esophageal cancer treated in the First Affiliated Hospital of Nanyang Medical College from January 2012 to June 2016 were selected as the study objects，the number of odd numbers was the control group，and the even number was the observation group，with 80 cases in each group. The 2 groups were given conventional chemotherapy，and the control group was given three dimensional conformal radiotherapy on the basis of conventional chemotherapy. The observation group was treated with Xiaoaiping Injection combined with thalidomide on the basis of the control group，21 days for a treatment cycle，both had 3 consecutive cycles and follow-up for 2 years. The short-term and long-term effects of the 2 groups were observed，and the levels of the serum tumor markers，VEGF and its receptors in the 2 groups were compared before and after treatment，the occurrence of toxic side effects in treatment and follow-up in the 2 groups were statisticsed. Results： The RR of the observation group was 75.00%，which was significantly higher than that 56.25% of the control group after treatment ( P <0.05); 1 year survival rate of the observation group was 96.25%，which was significantly higher than 86.25% of the control group ( P <0.05). The scores of main TCM symptoms such as dysphagia，pan-sputum and salivation，abdominal pain，diarrhea and quadriplegia in the 2 groups after treatment were significantly lower than those before treatment，and the scores in the observation group were significantly lower than those in the control group ( P <0.05 or P <0.01). The expression levels of MIP-3α，CA125，CEA，NSE，CYFRA21-1，VEGF，VEGFR-1 in serum of the 2 groups were significantly lower than those before treatment ( P <0.01)，the observation group was obviously lower than the control group ( P <0.01). The incidence of vomiting，leukopenia，radiation esophagitis and bone marrow depression in the observation group were significantly lower than those in the control group during treatment and follow-up ( P <0.05 or P <0.01). Conclusion： Xiaoaiping Injection combined with thalidomide adjuvant radiotherapy and chemotherapy can significantly reduce the levels of serum tumor markers in patients with middle and late esophageal cancer，inhibit the expression of VEGF and its receptor，improve the clinical symptoms and reduce the incidence of toxic side effects and improve the clinical efficacy., http://www.100md.com(南海峰 丁磊)
参见：首页 > 医疗版 > 疾病专题 > 消化内科 > 食管疾病 > 食管癌